Ophthalmic Drugs
•42 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (42)
%
| Company | Market Cap | Price |
|---|---|---|
|
TEPEZZA is an ocular/ophthalmic therapy, placing Amgen in Ophthalmic Drugs.
|
$156.00B |
$290.13
-2.04%
|
|
EYLEA and EYLEA HD place Regeneron in the ophthalmic drugs space.
|
$60.96B |
$564.63
-0.82%
|
|
Alcon markets Tryptyr (AR-15512), a prescription eye drop, representing a direct ophthalmic drug product.
|
$35.64B |
$72.05
-3.44%
|
|
Viatris has an eye care pipeline and eye-related therapeutics (acquired Oyster Point Pharma) supporting ophthalmic drug offerings.
|
$11.17B |
$9.52
-0.42%
|
|
Grifols is developing ophthalmic IG therapies (e.g., IG drops) for dry eye disease, an ophthalmic drug product line.
|
$6.41B |
$9.32
-1.58%
|
|
KB801 and KB803 are ophthalmic therapies, placing Krystal in ophthalmic drugs.
|
$5.24B |
$181.47
-4.43%
|
|
BLCO's MIEBO and XIIDRA are ophthalmic drugs targeting dry eye disease and associated inflammation, directly aligning with ophthalmic therapeutics.
|
$5.06B |
$14.32
-1.45%
|
|
Glaukos directly develops and sells ophthalmic drugs (iDose TR, Photrexa, Epioxa) for glaucoma and corneal health, representing core pharmaceutical offerings.
|
$4.72B |
$82.56
-5.10%
|
|
PBH's flagship eye-care products (e.g., Clear Eyes) are ophthalmic drugs, making Ophthalmic Drugs a direct product category.
|
$3.01B |
$61.00
-2.80%
|
|
XDEMVY is an ophthalmic drug (lotilaner ophthalmic solution 0.25%) and the company's flagship product, establishing a major ophthalmic drug category.
|
$2.95B |
$70.14
-0.09%
|
|
SYFOVRE is an ophthalmic drug (intravitreal pegcetacoplan) approved for geographic atrophy, representing the company's core marketed product.
|
$2.86B |
$22.76
-1.85%
|
|
Belite Bio focuses on ophthalmic drugs for Stargardt disease and geographic atrophy.
|
$2.31B |
$79.28
+1.03%
|
|
Ophthalmic drugs in Bausch Health's ophthalmic portfolio (Lumify and related eyedrops).
|
$2.24B |
$6.05
-4.87%
|
|
Ophthalmic Drugs covers the ILUVIEN and YUTIQ portfolio acquired by ANI, contributing to retina market expansion.
|
$1.99B |
$90.17
-1.51%
|
|
AXPAXLI and related assets are ophthalmic drugs/therapies delivered in the eye.
|
$1.94B |
$12.48
+1.88%
|
|
Avoralstat targets diabetic macular edema, placing part of BioCryst's pipeline in the ophthalmic drug category.
|
$1.51B |
$7.22
-0.48%
|
|
Harrow directly develops and sells ophthalmic drugs (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) and biosimilars in the ophthalmic space, i.e., ophthalmic drugs.
|
$1.38B |
$37.48
-8.02%
|
|
LENZ directly develops and markets an ophthalmic drug (VIZZ) indicated for presbyopia, fitting Ophthalmic Drugs as the core product category.
|
$1.09B |
$38.79
-17.03%
|
|
Lead asset is an ophthalmic drug (DURAVYU) delivered via a sustained-release implant for wet AMD and DME.
|
$956.48M |
$13.90
+4.91%
|
|
OCS is focused on developing ophthalmic drugs, including OCS-01 and OCS-02, for eye diseases.
|
$884.62M |
$21.09
-1.91%
|
|
Ophthalmic drug therapy: LCA4 program (AIPL1) targets an inherited retinal disease.
|
$630.06M |
$7.84
-11.11%
|
|
Kodiak directly develops ophthalmic drugs (intravitreal biologics) for retinal diseases.
|
$626.30M |
$11.87
-11.42%
|
|
ABBV-RGX-314 targets retinal diseases (wet AMD and diabetic retinopathy), aligning with Ophthalmic Drugs.
|
$547.75M |
$10.92
-9.83%
|
|
Ocugen's lead programs are ophthalmic gene therapies targeting eye diseases (RP, Stargardt, GA).
|
$516.90M |
$1.79
+1.41%
|
|
4D-150 targets ophthalmic indications (wet AMD/DME), placing FDMT in the Ophthalmic Drugs category as a direct product line.
|
$412.29M |
$8.90
-7.29%
|
|
OpRegen targets dry AMD, an ophthalmic indication, justifying Ophthalmic Drugs as a direct product category.
|
$385.92M |
$1.69
-1.74%
|
|
DT-168 is developed as an eye drop for Fuchs endothelial corneal dystrophy, aligning with Ophthalmic Drugs.
|
$346.86M |
$6.11
-4.08%
|
|
ANX007 is an ophthalmic drug (intravitreal Fab) for geographic atrophy, an eye condition.
|
$340.11M |
$3.10
-4.91%
|
|
Direct ophthalmic drug development with reproxalap for dry eye and ADX2191 intravitreal therapy for retinal conditions.
|
$330.02M |
$5.51
-4.67%
|
|
The therapy is an eye-focused (ophthalmic) cancer treatment for choroidal melanoma, fitting ophthalmic drugs.
|
$297.59M |
$5.92
-2.95%
|
|
Ophthalmic drug programs and ocular disease focus mentioned in the pipeline.
|
$231.14M |
$6.09
-10.44%
|
|
Lonigutamab targets an ophthalmic condition (TED), placing the company in Ophthalmic Drugs.
|
$228.61M |
$2.27
|
|
Surrozen' core ophthalmology-focused ophthalmic drug programs (SZN-8141/8143/113) target retinal diseases and corneal conditions.
|
$117.88M |
$13.77
-1.10%
|
|
Phentolamine Ophthalmic Solution 0.75% (RYZUMVI) is an ophthalmic drug generating licensing revenue for the company.
|
$116.94M |
$1.96
-2.97%
|
|
Ophthalmic drug therapies targeting eye diseases (wet AMD) are the core product category.
|
$112.60M |
$5.39
+0.09%
|
|
ABVC is developing ophthalmic drugs, including ABV-2002 corneal storage solution, and has ophthalmology licensing/partnership activity.
|
$50.99M |
$3.04
-7.03%
|
|
The company directly markets and commercializes an ophthalmic bevacizumab product (ONS-5010/LYTENAVA) for retinal diseases, which is a clear ophthalmic drug product.
|
$40.28M |
$1.20
-2.44%
|
|
Develops internal ophthalmic drug CLS-AX (axitinib injectable suspension) for suprachoroidal delivery, a drug product in development.
|
$20.62M |
$3.98
-8.72%
|
|
EyeCo/VisiRose represents an ophthalmic drug program using an RBS-based topical formulation (PV-305).
|
$16.11M |
$0.08
+0.93%
|
|
KALA's lead product KPI-012 is an ophthalmic therapy (cell-free MSC-S secretome) aimed at treating Persistent Corneal Epithelial Defects, aligning with Ophthalmic Drugs.
|
$9.23M |
$1.43
-7.74%
|
|
The company develops ophthalmic drugs (KIO-301 and KIO-104) for retinal diseases.
|
$8.22M |
$2.70
-4.26%
|
|
The company markets HOCl-based eye-care products (e.g., Lumacyn/Podiacyn), which fit the ophthalmic drugs category.
|
$6.64M |
$4.04
-6.05%
|
Loading industry metrics...
Loading comparison data...
